Generate Biomedicines Expands Leadership Team with the Arrival of Chief Medical Officer Alexandra Snyder, MD | national company

SOMERVILLE, Mass.–(BUSINESS WIRE)–July 26, 2022–

Generate Biomedicines, whose machine learning-based generative biology platform can rapidly invent new drugs in a wide range of previously unobtainable protein modalities and protein therapies, announced today that Alexandra Snyder, MD , was appointed chief medical officer to oversee all clinical matters.

This press release is multimedia. View the full press release here:

Alexandra Snyder, MD, Chief Medical Officer, Generate Biomedicines (Photo: Business Wire)

“We are excited to have Alex join the Generate Biomedicines team as we move our core programs through enabling IND studies and into the clinic,” said Mike Nally, CEO of Generate. “His impressive clinical experience, patient focus and proven leadership track record are crucial additions to our team as we pioneer the field of generative biology and pursue a broad pipeline of drugs.”

Dr. Snyder noted, “Generate is revolutionizing drug development with a powerful new approach to creating therapeutic proteins. I am thrilled to be part of such a talented team that will dramatically improve our ability to solve complex biological problems and help improve the lives of patients with a wide range of medical conditions.

Most recently, Dr. Snyder was a director of private equity firm Two River, where she was responsible for defining translational and clinical strategy and executing Two River’s portfolio of new biotech companies. Previously, she was Head of Translational Oncology at Merck. In this role, Dr. Snyder was responsible for conducting Merck-sponsored clinical trials of pipeline combination therapies at global sites and companion diagnostic strategy, biomarker programs, and quantitative pharmacology for oncology clinical trials. . Prior to joining industry, she practiced oncology at Memorial Sloan Kettering Cancer Center; she is currently a volunteer faculty member at Bellevue Hospital and New York University.

Dr. Snyder graduated summa cum laude from Princeton University with a degree in history and a minor in music. She received her medical training at Mount Sinai Medical School, earned the highest overall ranking, and was a resident in internal medicine at Mount Sinai Hospital and a medical oncology fellow at Memorial Sloan Kettering Cancer Center.

About generative biology

Generative biology represents a fundamental shift in therapeutic development that is driven by artificial intelligence. This new approach leaves behind the traditional trial and error methods of drug discovery and ushers in a new era of programmable drug engineering. Rather than “discovering” what is observable in the laboratory, Generate Biomedicines creates therapeutic opportunities by identifying specific biological processes involved in disease that can be modulated with a wide range of protein modalities. The promise of generative biology goes beyond existing proteins found in nature and can generate entirely new products, de novo proteins specially designed to meet an existing or emerging therapeutic need. Generative biology will enable therapeutic achievements never before possible, creating entirely new ways to treat all types of disease, dramatically increasing the success rate and reducing the time to drug discovery.

About Generate Biomedicines

Generate Biomedicines is the premier drug generation company, pioneering a machine learning-powered, multi-modality generative biology platform with the ability to generate new drugs on demand across a wide range of biological modalities. Through the seamless integration of computational and wet lab capabilities, Generate’s platform can dramatically improve the speed at which targets and therapies are identified and validated, the specificity of target engagement by generated proteins and the cost of identifying and developing clinical candidates. The Company’s platform represents a potentially fundamental shift in what is possible in the field of therapeutic development, addressing key drug discovery challenges and dramatically expanding the research space available for new biomedicines. Generate Biomedicines was founded by Flagship Pioneering after two years of fundamental research in its Labs unit and launched in 2020. Learn more about Generate Biomedicines by visiting or by following the company on Twitter and LinkedIn.

See the source version on

CONTACT: Generate Media:

Courtney Heath


[email protected]



SOURCE: Generating Biomedicines

Copyright BusinessWire 2022.

PUBLISHED: 07/26/2022 07:00/DISC: 07/26/2022 07:02

Copyright BusinessWire 2022.